MET and hepatocellular carcinoma: The tyrosine kinase receptor c-MET (MET) through its ligand, hepatocyte growth factor (HGF) leads to HCC progression by promoting cellular proliferation and invasion, as well as by mediating tyrosine kinase resistance.